Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Autor: Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac

Publikováno v: Breast, Vol 76, Iss , Pp 103761- (2024)

Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act

Externí odkaz: https://doaj.org/article/d3b96315025744e9a531e42906d8d57a

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Autor: Hideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, Gaetano Facchini, Sergio Fava, Duncan Wheatley, Kwong Chuen Leung, Mohammad Butt, Alberto Silva, Liliana Castillo, Vasilios Karavasilis, Ayse Ӧzatılgan, Simon Hitier, Evelyne B. Ecstein-Fraisse, Mustafa Ӧzgüroḡlu

Publikováno v: Journal of Global Oncology, Vol 4, Pp 1-12 (2018)

Purpose: There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, seque

Externí odkaz: https://doaj.org/article/898f38cc5b28407989d12bf6153544a3

Abstract P1-10-17: Axillary radiotherapy in selected patients with a preoperative diagnosis of lymph node involvement is a safe alternative to axillary lymph node dissection

Autor: Hamza A. Arabiyat, Iain Brown, Philip Drew, Rachel English, Mona Sulieman, Imran Abbas, Duncan Wheatley, Kali Potiszil, Alastair Thomson, Polly King

Publikováno v: Cancer Research. 83:P1-10

Introduction: Axillary lymph node dissection (ALND) is associated with significant morbidity. Randomised data [1,2] suggest that axillary radiotherapy (RT), or no further axillary treatment beyond sentinel node biopsy (SNB) may be safe. There are ver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e402a30fa7fd215752b808e648a5353f
https://doi.org/10.1158/1538-7445.sabcs22-p1-10-17

Data from Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Autor: David Schnell, Katy Pelling, Graham Temple, Martina Uttenreuther-Fischer, Ruth Plummer, Robert Laing, Helen Hatcher, Duncan Wheatley, Alistair Ring

Purpose: The HER2 mAb, trastuzumab, is a standard therapy for patients with HER2-positive breast cancer before acquired resistance. Afatinib, an irreversible, oral, small-molecule ErbB family blocker, shows clinical activity in trastuzumab-refractory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d58d36f170fdf9030083b9d81b5efd8
https://doi.org/10.1158/1078-0432.c.6524933

ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study

Autor: Ailsa J. Oswald, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John Bartlett, Tammy Piper, Eve Macdonald Chisholm, Michelle Welsh, Robert Hill, Lisa E. M. Hopcroft, Peter Barrett-Lee, David A. Cameron

Publikováno v: Oswald, A, Symeonides, S N, Wheatley, D, Chan, S, Murray Brunt, A, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Macdonald Chisholm, E, Welsh, M, Hill, R, Hopcroft, L E, Barrett-Lee, P & Cameron, D A 2023, ' ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-023-06873-8

Purpose The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05748b6217c9d05f9fb0f6d40ba51272
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050